Does your clinical management match the evidence? Treatment decisions after metformin in T2D

Faculty:

  • John Buse (chair, USA)
  • Nikolaus Marx (GER)
  • Naresh Kanumilli (UK)
  • Maria Jose Soler Romeo (ESP)

Description:
Four experts in primary care, endocrinology, cardiology and nephrology will come together to discuss a patient-centred and evidence-based approach to care in T2D after metformin, offering their clinical perspectives on the optimal and multifactorial management of an evolving patient case.

18:30 – 18:35

Introduction
18:35 – 19:15Does your clinical management match the evidence? Treatment decisions after metformin in T2D
19:15 – 19:30Panel discussion and Q&A


The content for empagliflozin contained in this virtual session is intended for delegates from countries regulated by the European Medicines Agency (EMA), and does not include healthcare professionals in the UK or Ireland. Prescribing information may vary depending on local approval in each country inside and outside of Europe. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.